Repligen reported 12.5% year-on-year organic revenue growth and adjusted EBITDA margin expansion of 1.9 percentage points. Management now expects full-year adjusted EBITDA margin of 21%, at the top of its previous guidance range of 20.6%-21.0%.
Repligen offers investors exposure to the rapidly growing and moatworthy bioprocessing industry and its market-leading product offerings.
Repligen’s adjusted EBITDA margins are around 20%, lagging the industry average of the high 20s.
Metric | RGEN | TMO | SRT3 |
|---|---|---|---|
Price/Earnings (Normalized) | 139.18 | 29.05 | 81.61 |
Price/Book Value | 4.72 | 4.86 | 6.84 |
Price/Sales | 12.20 | 5.67 | 5.49 |
Price/Cash Flow | 51.96 | 25.75 | 27.05 |
Metric | RGEN | TMO | SRT3 |
|---|---|---|---|
Quick Ratio | 8.07 | 1.23 | 0.43 |
Current Ratio | 9.88 | 1.81 | 1.07 |
Interest Coverage | 1.37 | 5.52 | 4.03 |
Metric | RGEN | TMO | SRT3 |
|---|---|---|---|
Return on Assets (Normalized) | 3.93% | 8.32% | 3.58% |
Return on Equity (Normalized) | 5.50% | 17.48% | 12.52% |
Return on Invested Capital (Normalized) | 4.74% | 10.45% | 5.41% |
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Intuitive Surgical Inc ISRG | LOCK|H#Dct$hw | LOCK|>c | $156B | |||
| Becton Dickinson & Co BDX | LOCK|FZD | LOCK|pR$> | $58B | |||
| Alcon Inc ALC | LOCK|&F@Y@Px | LOCK|%#rd | $36B | |||
| Medline Inc Ordinary Shares - Class A MDLN | LOCK|j?>$Bj^ | LOCK|SVr$K | $36B | |||
| ResMed Inc RMD | LOCK|?gv<p!Q | LOCK|>y?g@ | $33B | |||
| West Pharmaceutical Services Inc WST | LOCK|#??X@&F | LOCK|SNw | $29B | |||
| Solventum Corp SOLV | LOCK|#bZds$M | LOCK|&T< | $15B | |||
| Baxter International Inc BAX | LOCK|$b | LOCK|@vt> | $14B | |||
| Align Technology Inc ALGN | LOCK|$q&C>k% | LOCK|&!#$r | $12B | |||
| The Cooper Companies Inc COO | LOCK|##^D$R# | LOCK|@Jg^ | $12B |
United States